Wall Street brokerages expect Seres Therapeutics Inc (NASDAQ:MCRB) to announce ($0.30) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Seres Therapeutics’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.21). Seres Therapeutics posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 44.4%. The firm is expected to report its next quarterly earnings report on Thursday, November 14th.
On average, analysts expect that Seres Therapeutics will report full-year earnings of ($1.55) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.16). For the next year, analysts expect that the company will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.66) to ($0.77). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.17. The company had revenue of $12.53 million for the quarter, compared to analyst estimates of $10.29 million.
A number of research analysts have weighed in on MCRB shares. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Thursday, July 4th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Seres Therapeutics in a research note on Friday, May 3rd. Finally, Jefferies Financial Group reduced their price target on Seres Therapeutics from $6.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Seres Therapeutics has an average rating of “Buy” and an average price target of $10.25.
In other news, Director Noubar Afeyan bought 8,888,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were acquired at an average cost of $2.25 per share, with a total value of $19,999,998.00. Following the transaction, the director now owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 37.00% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth about $8,050,000. Walleye Trading Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth about $91,000. Walleye Trading LLC bought a new position in Seres Therapeutics in the second quarter worth about $87,000. CVI Holdings LLC bought a new position in Seres Therapeutics in the second quarter worth about $727,000. Finally, Jane Street Group LLC bought a new position in Seres Therapeutics in the second quarter worth about $369,000.
NASDAQ:MCRB traded up $0.12 during trading hours on Monday, reaching $2.97. 265,800 shares of the company traded hands, compared to its average volume of 290,097. The firm’s 50-day moving average is $2.86 and its 200-day moving average is $4.72. The stock has a market cap of $207.63 million, a P/E ratio of -1.22 and a beta of 2.03. Seres Therapeutics has a 1-year low of $2.02 and a 1-year high of $9.26.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Read More: How to Profit and Limit Losses With Stop Orders
Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.